Squire Patton Boggs is pleased to announce that life sciences experts Dr. Rüdiger Herrmann and Jochen Eimer have today joined the firm in Frankfurt as a partner and director, respectively, from McDermott Will & Emery LLP. Their arrival further strengthens the depth and scope of Squire Patton Boggs’ German Corporate Practice and its international Life Sciences Group.
Rüdiger Herrmann assists national and international clients in the biotechnology and pharmaceutical sectors on mergers and acquisitions, joint ventures and licensing agreements, private equity and venture capital transactions, as well as IP-related matters. He has a particularly deep experience advising on life sciences related cross-border matters in Europe, the United States, China and Taiwan.
Jochen Eimer also focuses his practice on transactions in the biotech and pharma as well as the medical devices sectors with additional expertise in regulatory matters as well as licensing, collaboration, R&D and other industry specific commercial agreements.
“Rüdiger’s and Jochen’s robust global life sciences sector expertise fits square with our strategic goals for further growth, particularly in times of the pandemic,” comments Horst Daniel, managing partner of Squire Patton Boggs’ Frankfurt office. “With this team, we have significantly enhanced our ability to offer in-depth, specialist expertise in an area that is literally vital in Germany and around the globe.”
Stephen E. Chelberg, Asia Pacific chair of the firm’s global Corporate Practice and leader of the Life Sciences Industry Group adds: “Whether advising start-ups or established multinationals, our life sciences group has the legal, policy, commercial and technical skills to help develop, market, license and protect innovative products worldwide. I am delighted that we have now strengthened this offering in Germany, one of the key markets in the sector globally, through the addition of Rüdiger and Jochen two of the country’s leading practitioners.”
“We are very pleased to join Squire Patton Boggs and look forward to contributing to the success of their well-respected life sciences practice”, says Rüdiger Herrmann. “The firm’s truly global presence, with access to over 1,500 lawyers in 45 offices across 20 countries, will be of great benefit to our clients.”